Thomas J. Rutherford, MD, PhD
Director Gynecologic Oncology
Yale University School of Medicine
333 Cedar Street, Box 208063
New Haven,
CT
USA
06520-8063
Papers:
140
Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo
182
Cervical adenocarcinoma in situ: an institutional retrospective review of surgical management and outcome
191
Antitumor activity of the ribonucleotide reductase inhibitor triapine alone or in combination with paclitaxel
262
Choice of adjuvant chemotherapy following neoadjuvant carboplatin/paclitaxel and delayed primary debulking
356
Neratinib, an irreversible pan-ErbB receptor inhibitor, is highly effective against primary cervical cancer cell lines harboring HER2/neu gene mutations
401
Mutations in the PIK3 pathway as a major determinant of trastuzumab resistance in uterine serous carcinoma